Albinism, from the Latin albus, meaning "white," is a group of heritable conditions associated with decreased or absent melanin in ectoderm-derived tissues (most notably the skin, hair, and eyes), yielding a characteristic pallor. The most commonly thought of presentation is that of oculocutaneous albinism (OCA). OCA is a group of phenotypically similar genetic disorders derived from errors in melanin synthesis. As the name implies, the most dramatic effects are in the eyes and skin. The skin manifestations are more heterogeneous and appear along with a spectrum of severity depending upon the subtype of OCA. The ocular structures rely upon melanin for signaling as they develop, in utero; thus, misrouted optic nerve fibers yield more uniform ocular manifestations of the disorder.[1][2][3]
To date, seven types of nonsyndromic albinism (OCA1 to OCA7) have been described. These are all due to isolated genetic mutations whose constellation of signs and symptoms do not manifest so broadly that they can be classified as syndromic. A discussion on albinism, however, would be incomplete without the mention of isolated ocular albinism (OA1) and the syndromic albinisms: Hermansky-Pudlak syndrome (HPS) and Chediak-Higashi syndrome (CHS). The syndromic albinisms have the same hallmark lack of dermal and ocular pigment as OCA. They, however, involve genes that encode for proteins that have more extensive applications to cellular function. Loss-of-function mutations in these genes, therefore, yield predictable systemic consequences associated with the syndromes mentioned. Examples include inactivation of genes involved in lysosomal synthesis (and not simply melanin synthesis) that lead to bleeding diathesis in HPS and propinquity to infection in CHS. Other conditions may present like albinism with congenital nystagmus and/or generalized hypopigmentation. Most of these are included in the Differential Diagnosis section. Of special mention is a pair of syndromes that derive their albino-like features because of deletions in the same genes that are mutated in OCA type 2: Angelman (AS) and Prader-Willi (PWS) syndromes.[4][5][6]
Albinism, in any of its forms, is the result of heritable mutations that lead to defective melanocytes, unable to properly synthesize melanin or distribute it through dermal tissues. The exact number of melanocytes in the skin are preserved, unlike conditions such as piebaldism and vitiligo, where melanocytes are absent. The specific gene mutations causing each form or albinism are mentioned below in the "History and Physical" section.
Occurrence is estimated at 1:17,000 to 1:20,000 overall. Approximately one in 70 individuals carry an OCA-mutated allele, with the OCA2 mutation being the most common worldwide. OCA2 is common in sub-Saharan Africa since cultural norms permit consanguineous marriages, allowing prevalence reach 1 in 1000 and a phenomenon called pseudo-dominance where the recessive allele burden is so high in a given family, that the recessive trait is disproportionately represented. The prevalence of individual forms of albinism are included below:
Melanocytes are derived from neural crest ectoderm during embryonic development and migrate into the skin, eyes, hair, and inner ear. They represent about 5% to 10% of the cell population in the epidermal basal layer, and this number remains unaffected in albinism. Melanocytes contain specialized melanin-producing organelles (melanosomes) that usually develop by week seven embryonically. The only other tissue capable of synthesizing melanin are retinal pigment epithelium, and it is not of neural crest origin. Melanin is most known for its role in ultraviolet (UV) protection, but it also has roles in both embryologic development of the ocular structures and oculoneural pathways. The two most common forms of melanin are eumelanin and pheomelanin. Eumelanin imbues skin with black or brown coloration and plays a role in protecting the skin against ultraviolet radiation B (UVB) damage by absorbing and dissipating the rays and their carcinogenic DNA cross-linking effects. Pheomelanin is not UV protective, and people who predominantly have pheomelanin are Fitzpatrick scale 1, with red or blond hair and light-colored, ruddy skin. The synthesis of eumelanin over pheomelanin is stimulated by activation of melanocortin one receptors (coded by the MC1R gene) on melanocytes.[7]
The first (and rate-limiting) step in eumelanin synthesis involves the oxidation of L-tyrosine to DOPA by tyrosinase. Mutations in the tyrosinase gene, as seen in OCA1A, leads to complete loss of the ability to produce eumelanin. The loss-of-function mutations in any type of OCA, however, impair eumelanin synthesis directly or affect melanosome maturation but may leave pheomelanin levels unaffected. Most of the non-OCA1A pigmentation that accounts for the varied phenotypes is pheomelanin, which imbues the skin, hair, and iris with color. Syndromic albinism does not always affect melanin synthesis so much as it does the production or distribution of melanosomes through the basal layer into keratinocytes from melanocytes.
The two significant results of hypomelanosis can be divided into dermatological and ophthalmologic consequences. Since eumelanin is photo-protective, albinism leads to increased risk of sun-damage (solar lentigines, actinic keratoses, solar erythema) and UV-associated malignancies (especially squamous cell carcinomas). Melanin acts as an inducer and organizer of formation of the fovea, optic nerves, optic tracts, and visual cortex, in utero. In albinism, the fovea fails to develop as robustly as normal and is hypoplastic or even absent. Melanin in utero cues the migration of developing optic nerve fibers. Some crossover of nerve fibers from each eye at the optic chiasm to the contralateral occipital lobe is necessary for binocular vision. In albinism, however, some axons that originate in the retinal ganglion cells project mistakenly to the contralateral hemisphere dorsal lateral geniculate nucleus. This means an increase in optic fiber crossover. Nerve fibers misrouted from the organ or reception (the eye) to the organ of perception (the brain) further contributes to binocular vision deficits, manifesting as strabismus. The occipital lobe in albinism also shows decreased gyrification (theorized to be due to a dearth of foveal input), and localized increases in cortical thickness. The latter finding has also been found in congenitally blind subjects. In summary, complete absence or even partial melanin deficiency in utero leads to ocular structure malformation and optic tract misrouting and creates a multitude of irreversible intraocular (refractive) and extraocular (oculomotor or nonrefractive) problems. Visual acuity usually ranges from 20/60 to 20/400.
The genetic aberrations specific to each form of OCA, syndromic albinisms, and selected albinism-associated disorders are included below:
Hematoxylin and eosin staining does not reveal any defects in the skin. Melanin staining and melanocyte-special stains (dopa oxidase or HMB45) will be slight to moderately positive since pheomelanin and melanocytes are still present in the skin. Tissues pathology is rarely done outside of evaluation for dermal malignancies, as it is not necessary to confirm the diagnosis.
Cutaneous findings vary widely, but the most dramatic features occur in OCA1A due to complete lack of melanin. The white hair, white eyelashes, white skin, and pink eyes are typical of what the general populations consider an albino. Some darkening over time from shampoos and water minerals may occur but spares the eyelashes and eyebrows. Every other form of albinism has some residual pigmentation that can increase with time, mostly through pheomelanin. For this reason, comparison with family members may be vital in raising the clinical suspicion of albinism, especially if ocular manifestations are mild. Relative hypopigmentation in Caucasian families is more difficult to appreciate than in families with more pigment.
Ocular findings are the more debilitating clinical feature due to its effect on vision; they can be divided into refractive and nonrefractive errors.
The most common phenotypes of each of the forms of albinism, including visual deficit ranges, are included below:
Early diagnosis is most important to manage ocular symptoms and maximize visual potential, which has further ramifications on general safety and wellbeing, education, self-esteem, and cognitive development. Family and providers are not always alerted by hypopigmentation of skin, hair, and eyelashes, except in the context of family members who are constitutionally darker pigmented and the contrast is more striking. Iris hypopigmentation may be overlooked initially as it is not uncommon in infants for iridic melanin deposits to take six to nine months to reach adult coloration. Ocular manifestations usually grip the attention of caregivers or physicians within the first 3 to 6 months of life. Pediatricians often suspect OCA at the 2 or 4-month well-baby check. While patchy congenital hypopigmentation may lead clinicians to investigate piebaldism or Waardenburg syndrome, generalized hypopigmentation with nystagmus and normal hearing is sufficient to pursue an evaluation for albinism, be it OCA or one of the syndromic forms.
Special attention needs to be given to associated symptoms (recurrent infections in CHD, bleeding in HPS, and mental retardation in Cross syndrome, Angelman syndrome, or Prader-Willi) so that a diagnosis of syndromic albinism is not missed.
Ophthalmology can help confirm the diagnosis with testing. Characteristic ocular changes (infantile nystagmus, photophobia, reduced iris pigment with transillumination, reduced retinal pigment, visualization of choroidal blood vessels on a fundoscopic exam, foveal hypoplasia, decreased visual acuity, strabismus, misrouting of optic nerves on selective VEP exam) combined with cutaneous hypopigmentation.
Generalized congenital hypopigmentation with normal ocular motion or normal ophthalmic examination is not OCA, and an assessment for nutritional or metabolic disorders should ensue. These include phenylketonuria, homocystinuria, histidinemia, Menkes syndrome (copper deficiency), and kwashiorkor. If the patient has impaired hearing, Tietz syndrome should be considered.
Molecular genetic testing can confirm the diagnosis but is not routinely done. It is expensive and best done using multigene or comprehensive genome sequencing. Clinical diagnosis, especially incorporating a complete ophthalmologic exam, is sufficient. An exception is to distinguish OCA1A and OCA1B in infancy, as they can be phenotypically identical during the first year of life. If patients develop some pigmentation after the first year of life, genetic testing may be useful to distinguish OCA1B from clinically similar OCA2.
Carriers are asymptomatic heterozygotes of autosomal recessive genes. Carrier testing makes sense in child-bearing age family members of albino patients but requires the pathogenic variant in the family to be already identified, thus necessitating gene sequencing of the albino, themselves.
Prenatal diagnosis or preimplantation genetic diagnosis can similarly be made if the pathogenic variant is already identified.
No specific serological tests or imaging needs to be performed in the diagnosis or routine management of albinism.
Management of Dermal Manifestations
There is no substitute for lifelong sun protection in albinism, and the importance cannot be overestimated. Subjects should be educated on avoidance of prolonged UV light exposure (sun, tanning beds) and avoidance of medications that increase photosensitivity. Any outdoor activities, no matter how brief, should be preceded by the application of sunscreen (SPF 30+) with liberal and frequent reapplication (every 2 hours) when in the sun. No good studies support the use of high SPF, but some resources recommend SPF 50 or higher. Additional protection can be enlisted with the use of protective clothing and eyewear (hats, UPF-labeled clothing, long-sleeves, long pants, collared shirts, socks, UV protective sunglasses). Photophobia can be managed with dark lensed glasses, but because of the resultant vision reduction, some patients opt for brimmed hats. Self-examination and self-education on melanoma ABCDE criteria, prompt referral to dermatology for any suspicious or changing lesions, such as (1) new lesions in sun-exposed areas, (2) painful, itching, bleeding, nonhealing, changing lesions, or (3) asymmetrical, irregularly bordered, variably colored, diameter greater than 6 mm, evolving lesions. Lifelong, periodic skin examinations (once to twice per year) with dermatology for early detection and treatment of skin cancers. Referrals to pediatric dermatology should be early to illuminate the benefit and decode the terminology of sun-protective options. Surveillance should start at adolescence, as skin cancer may appear as early as the teenage years. Special attention from providers to changes in pink and red lesion, since most melanoma in OCA is amelanotic melanoma.[8]
Management of Eye Abnormalities
Nystagmus naturally decreases over time. Additionally, individuals enact learn to adjust head posture to time the gaze position the yields the lowest nystagmic amplitude. This position is called the nystagmus null point. Eye muscle surgery can improve ocular alignment, improve head posture, and improve vision only in severe cases, but surgery may need to be repeated several times. Unless strabismus is severe, it is usually not necessary unless it is pursued for cosmetic reasons. Ophthalmic evaluation for optical correction 2 to 4 times per year (age 1 and 2), 1 to 3 times per year (age 3 to 6), annually (age 5 to 18), then every 2 to 3 years (adults). Refractive errors require treatment with corrective lenses, preferably by 4 to 6 months of age with frequent changes in prescriptions in the first years of life. Even with refractive correction, vision may never fully normalize because of irreversible foveal hypoplasia. Lenses that darken in sunlight help with photophobia but decrease vision. Lenses should have UV protection. Bifocals and low-vision aids may also be considered in older children and adults. Teaching aids and special classroom considerations (high contrast reading material, large print texts and worksheets, close-to-board seating, magnification settings on computers, among others) can help overcome the educational delays associated with visual deficits.
Management of the Inheritable Nature of the Condition
Genetics consultation before childbearing years is beneficial to parents of albino children considering future offspring, the patient with albinism and their siblings. Albinism is an obligate homozygote condition with a 100% chance of passing on their defective gene. Coordinated genetic testing of the nonaffected partner is possible if the pathogenic variant is known. This will confirm the offspring have the potential to inherit the condition, if the partner is a carrier of the same pathogenic variant, or just be obligate carriers if the partner has only wild-type genes. A couple who has already had an albino child has a 25% chance of having another child with albinism, a 50% chance of producing carrier offspring, and 25% of producing non-carrier offspring. This is assuming that one of the parents is not albino, in which case the chance of producing a second albino offspring is 50% after a confirmed albino offspring. The fact than non-albino siblings have a 67% chance of being carriers is important to convey before they consider childbearing. Of note, if two parents carry genes for different types of albinism (for example, a patient with OCA2 and a carrier for OCA1), no children will be born with albinism, but the children are at risk for being heterozygous for both mutant alleles.
Direct Therapeutic Modalities
Nitisinone triggers tyrosine accumulation in blood and mouse models have suggested that it could improve pigmentation in OCA1B subjects, but a clinical trial is currently underway. Aminoglycosides are a potential and unconfirmed therapy. Despite anecdotal reports, L-DOPA did not result in any improvement in visual acuity in a study of 45 patients. Adeno-associated viruses (AAV) vectors is a potential gene therapy introducing a functional copy of the tyrosinase gene in OCA1 and OA1 patients.
Based upon similar ocular findings (early onset nystagmus):
Based on hair and cutaneous finding (hypopigmentation):
Life expectancy within the non-syndromic OCA population is comparable to the general population. There is an increased mortality risk due to skin cancer. This risk changes based on the amount of relative sun exposure in a geographic area and certain socioeconomic issues. These socioeconomic issues include limited access to sunscreen, limited education on sun-protective measures, cultural differences in dress, limited access to healthcare professionals for surveillance leading to late presentation and late treatment, inability to comply with or complete treatment courses. In these same lower socioeconomic regions, there is often a palpable stigma associated with albinism, and the afflicted may be victims of persecution, prejudice, and violence. Some albinos have even been murdered as their organs are highly valued on the black market. Albinos have normal intelligence compared with the general population. There is some delayed visual maturation, and this can lead to educational delay if not addressed early enough. Furthermore, poor self-image and social alienation can lead to feelings of isolation and depression. Albinos do have an increased rate of attention deficit disorder.
Visual deficits can lead to the following:
Infection risk in Chediak-Higashi syndrome
Bleeding Diathesis in Hermansky-Pudlak syndrome
Solar damage: Pachydermia (coarse, rough, thick skin), actinic keratoses, solar lentigines (in non-OCA1A albinos), solar erythema
Malignancy: Basal and squamous cell carcinomas (BCC, SCC). SCC is by far the most common malignancy reported among albinos (representing more than 75% of cases of malignancy), developing as early as the teens. One study found that more than 70% of them were diagnosed on the head and neck areas. Another study found the head, face, and hands equally affected at approximately 20% each. Albinism increases the relative risk of SCC as much as 1000 times, at least in the African population. Cumulative sun exposure is the major risk factor, with the incidence of cancers increasing with patient age. BCC account for about 24% of malignancies, with the remaining 1% being melanoma. Melanomas are rare in albinos with only a few case reports in the literature, despite melanocytes still being present in the skin in the same relative number. Surprisingly, melanomas often occur in non-exposed areas, which speaks against UV-radiation being the culprit. Practitioners need to have a high level of suspicion since these lesions are both rare and tend to be amelanotic in albinos.
Early consultation to ophthalmology and dermatology, as mentioned above. Family referral to geneticist may be beneficial.
Albinism is a relatively common genetic disorder which affects many organ systems. Thus, the disorder is best managed by an interprofessional team. Vision deficits are the major source of debility in non-syndromic albinism subjects. These should be addressed early to maximize outcomes and limit the social and educational impact. Squamous cell carcinomas are the most common malignancy in albinism, which can increase the relative risk as much as 1000 times. Albinism is not curable. The focus should be on early assessment and correction of visual deficits and lifelong, risk-factor modification, early detection, and treatment of the skin malignancies. Early consultation to ophthalmology and dermatology, as mentioned above. Family referral to geneticist may be beneficial.
[1] | Jung JH,Hye Oh E,Shin JH,Kim HS,Young Choi S,Choi KD,Lee C,Choi JH, Identification of a novel {i}GPR143{/i} mutation in X-linked ocular albinism with marked intrafamilial phenotypic variability. Journal of genetics. 2018 Dec; [PubMed PMID: 30555098] |
[2] | Hamid MA,Mehta MC,Kuppermann BD, Multimodal imaging in a patient with Prader-Willi syndrome. International journal of retina and vitreous. 2018; [PubMed PMID: 30519487] |
[3] | Baulier E,Garcia Diaz A,Corneo B,Farber DB, Generation of a human Ocular Albinism type 1 iPSC line, SEIi001-A, with a mutation in GPR143. Stem cell research. 2018 Dec; [PubMed PMID: 30513407] |
[4] | Teramae A,Kobayashi Y,Kunimoto H,Nakajima K,Suzuki T,Tsuruta D,Fukai K, The Molecular Basis of Chemical Chaperone Therapy for Oculocutaneous Albinism Type 1A. The Journal of investigative dermatology. 2018 Nov 14; [PubMed PMID: 30447237] |
[5] | Garcia Galvão LE,Tomaz R,de Sá Gonçalves H, Daylight Photodynamic Therapy in the Treatment of Actinic Keratosis in Carriers of Oculocutaneous Albinism: Report of Three Cases. Actas dermo-sifiliograficas. 2018 Nov 17; [PubMed PMID: 30458957] |
[6] | Han CG,O'Brien KJ,Coon LM,Majerus JA,Huryn LA,Haroutunian SG,Moka N,Introne WJ,Macnamara E,Gahl WA,Malicdan MCV,Chen D,Krishnan K,Gochuico BR, Severe bleeding with subclinical oculocutaneous albinism in a patient with a novel HPS6 missense variant. American journal of medical genetics. Part A. 2018 Oct 4; [PubMed PMID: 30369044] |
[7] | Hayashi M,Suzuki T, Oculocutaneous Albinism Type 4 1993; [PubMed PMID: 20301683] |
[8] | Morice-Picard F,Taïeb C,Marti A,Gliksohn A,Bennani M,Bodemer C,Ezzedine K, Burden of albinism: development and validation of a burden assessment tool. Orphanet journal of rare diseases. 2018 Sep 18; [PubMed PMID: 30227882] |